inhibitory glp 1 GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1 receptor agonists | How
Description
Where obesity is still approached episodically, treatment interruptions become more likely
They are primarily peptide-based and engineered for prolonged activity, improving metabolic control in patients with diabetes and obesity
Dose adjustment, temporary treatment interruption, or switching to an alternative therapy may be appropriate
69705-5/asset/079012c9-a24f-4391-ba39-2f5d03668f6f/main.assets/gr1_lrg.jpg)
Further, the absolute risk reduction is small, which translates into a comparatively high number needed to treat of 67
As a result, it is critical that you hire an attorney with experience in this area to help you
